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Abstract
Background: Increased protein citrullination and peptidylarginine deiminases (PADIs), which catalyze the citrullination
process, are central in Rheumatoid arthritis pathogenesis and probably involved in the initial steps towards autoimmunity.
Approximately, 10% of RA patients develop clinically significantly ILD. A possible shared role of protein citrullination in
rheumatoid arthritis associated interstitial lung disease (RA-ILD), and idiopathic pulmonary fibrosis (IPF) pathogenesis
remains unclear.
Methods: We evaluated PADI2 and PADI4 mRNA expression in bronchoalveolar lavage fluid (BALF) cells of 59 patients with
IPF, 27 patients RA-ILD and 10 healthy controls. PADI 2 and 4 expression was analyzed by western blot and
immunohistochemistry. Citrullinated protein levels were also quantified.
Results: PADI4 mRNA and protein levels were higher in RA-ILD and IPF than controls. Furthermore, PADI4 mRNA levels
showed an increase among smokers in RA-ILD. PADI4 expression was detected in granulocytes and macrophages in all
groups, with the strongest cytoplasmic expression observed in granulocytes in RA-ILD and IPF. PADI2 mRNA and
immunostaining of BAL cells, were similar in all groups among smokers. Overall, stronger staining was observed in current
smokers. Citrullinated peptides were significantly increased in IPF compared to RA-ILD and controls. In RA-ILD, protein
citrullination strongly correlated with PADI4 expression and anti-citrullinated protein antibodies (ACPAs).
Conclusions: These results suggest that the citrullination pathway is upregulated in IPF and in RA-ILD.
Keywords: Citrullination, Peptidylarginine deiminases, Smoking, Idiopathic pulmonary fibrosis, Rheumatoid arthritis,
Interstitial lung disease, Pathogenesis
Background
Rheumatoid arthritis (RA) is an autoimmune disease,
characterized by chronic polyarthritis of the small joints
and is thought to be driven by antibodies against citrulli-
nated proteins (ACPAs). Citrullination has been suggested
to grant an important step in braking immunotolerance or
enhancing autoimmune reactivity [1]. ACPAs are positive
in about 60–50% of RA patients and may be detected more
than 10 years before joint inflammation thus suggesting
that RA could be generated outside the joints [2, 3].
Citrullination is a post-translational modification of the
amino acid arginine into citrulline. It is a Ca2+ dependent
reaction, catalyzed by peptidylarginine deiminases (PADIs)
[4]. PADIs are activated by higher concentrations of cal-
cium in cells undergoing apoptosis and during inflamma-
tory responses [5]. Among the known isoforms of PADIs
[6], PADI2 and PADI4 have been previously associated
with RA pathogenesis [7]. PADI4 polymorphisms leading
to higher enzyme levels have been associated with RA
susceptibility and HRCT abnormalities in lungs [8]. PADI4
is mainly expressed in macrophages, neutrophils, and eo-
sinophils and triggers neutrophil extracellular traps
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(NETs) formation [9], whereas PADI2 is highly expressed
in macrophages [10, 11]. Citrullinated proteins, most
commonly associated with RA are vimentin, filaggrin,
cytokeratin and fibrin and have been detected in extra-
articular sites [1, 4, 12, 13].
Lungs are the most common site of extra-articular in-
volvement and is associated with autoantibody positivity
[14]. Subclinical ILD is identified in 60% of RA patients
and clinically significant ILD is present in 10% [15]. UIP
is the most common pattern in clinical significant RA-
ILD [16], with similar phenotype and mortality as Idio-
pathic Pulmonary Fibrosis (IPF). Smoking, a known risk
factor for both RA and IPF, predispose for lung involve-
ment in RA [14, 17]. Additionally, smoking has been as-
sociated with increased concentrations of PADI2 in
bronchoalveolar lavage cells [18] and citrullinated pro-
teins are present in the lungs of smokers [19].
Research for the primary pathogenetic events of idio-
pathic pulmonary fibrosis (IPF) has intensified in recent
years, however remain elusive [20]. Indirect evidence of a
smoking-related pathogenetic hypothesis exists [21, 22],
while citrullination of the lung tissue has already been re-
ported in IPF [23]. The association between smoking and
IPF justify the exploration of common pathogenetic path-
ways linked to smoking, including citrullination. With this
background, we assessed the activity of the citrullination
pathway via the examination of PADI2 and 4 enzyme ex-
pression and protein citrullination levels, in BAL cells, in
RA-associated ILD compared to IPF and control subjects.
Materials and methods
Patients
Patients were classified as ever smokers and non-smokers.
Pulmonary function tests, performed within 1 month of
CT, included FEV1, FVC, and DLCO corrected for
hemoglobin concentration, expressed as percentages of
the predicted normal values. The composite physiologic
index (CPI) was calculated as 91.0 – (0.65 × percent pre-
dicted DLCO) – (0.53 × percent predicted FVC) + (0.34 ×
percentage predicted FEV1) [24].
Ninety-six (96) subjects were retrospectively enrolled
in this study, consisting of patients with IPF (n = 59), pa-
tients with RA-ILD (n = 27), and healthy control subjects
(n = 10). 43 IPF patients and 20 RA-ILD patients were
being treated at the Interstitial Lung Disease Unit, Royal
Brompton Hospital, Imperial College, London, UK and
the remaining 16 IPF patients, 7 RA-ILD patients and 10
healthy control subjects were recruited from the De-
partment of Thoracic Medicine, University Hospital of
Heraklion, Crete, Greece.
IPF group: The diagnosis of IPF was based on using
ATS/ERS clinical and HRCT criteria (n = 54) or on open
or video-assisted thoracoscopic biopsy, with all biopsies
reviewed by the same two histopathologists (n = 5), [25].
In accordance with the aforementioned criteria any
patient presenting any known cause of pulmonary fibro-
sis, such as a systemic connective tissue disorder, was
excluded from this study using both immunologic
screening and rheumatologic clinical evaluation [25]. All
IPF patients were newly diagnosed and had not received
previous treatment.
RA-ILD group: Criteria for the diagnosis of CTD in-
cluded the American College of Rheumatology (ACR)
1987 revised criteria for the classification of rheumatoid
arthritis (RA) [26]; Patients with RA-ILD had HRCT find-
ings indicative of definite interstitial lung disease, evalu-
ated by two independent assessors. Patients used in our
cohort presented with a variety of patterns. As determined
by HRCT, RA-ILD was classified as Usual Interstitial
Pneumonia-CPFE in twelve (12) out of twenty-seven (27)
patients, Fibrotic Nonspecific Interstitial Pneumonia in
nine (9), Organizing pneumonia in one (1), Fibrotic NSIP
overlapping with Organizing pneumonia in one (1), Dif-
fuse alveolar damage in one (1) and Unclassifiable ILD
(bronchiectasis with fibrotic changes, bronchiolitis with fi-
brotic changes) in three [27].
Control group: The control subjects were patients
undergoing bronchoscopy for the investigation of haem-
optysis, without any overt pulmonary comorbidities and
with normal bronchoscopic findings and cytology re-
sults. There were all current or former smokers. Since
controls were healthy subjects no pulmonary function
test was performed.
Informed consent was obtained from all patients who
participated in this study. The study was approved by
the Ethics Committees of the University Hospital of Her-
aklion (IRB number: 1045 and17030) and the Royal
Brompton Hospital (REC reference 13/LO/0857).
Methods
Pulmonary function tests
All patients were evaluated with complete pulmonary
function tests (PFTs), including spirometry, measure-
ment of lung volumes (forced expiratory volume in one
second – FEV1, forced vital capacity – FVC) and diffu-
sion capacity (DLco). Spirometry, lung volumes using the
helium-dilution technique and DLCO (corrected for
haemoglobin) using the single breath technique were per-
formed using a computerized system (Jaeger 2.12; Master-
Lab, Würzburg, Germany). Predicted values were obtained
from the standardized lung function testing of the Euro-
pean Coal and Steel Community, Luxembourg (1993).
BAL fluid processing
BALF was obtained from all patients as previously de-
scribed [28]. Briefly, a flexible bronchoscope was wedged
into a subsegmental bronchus of a predetermined region
of interest based on radiographical findings. A BALF
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technique was performed by instilling a total of 240 mL
of normal saline in 60-mL aliquots, each retrieved by
low suction. The BALF fractions were pooled and split
equally into two samples. One sample was sent to the
clinical microbiology and cytology laboratory and the
other sample was placed on ice and used for this re-
search. These samples were filtered through 70 nm cell
strainers and centrifuged at 400 g for 5 min at 4 °C.
Total cell counts were determined.
RNA extraction:
Total RNA was extracted from 1.5 million cell BALF
sample using the TRIzol® reagent (Invitrogen, Carlsband,
CA) according to the manufacturer’s instructions. In
summary, chloroform is added and the specimens are
centrifuged. Total RNA is precipitated from the super-
natant with isopropanol, it is washed with 75% ethanol
and it is suspended in 50 μl DEPC-treated water. RNA
concentration and purity are calculated following meas-
urement of its 260-nm absorbance and 260/280-nm ab-
sorbance ratio on a UV spectrophotometer.
Reverse transcription PCR (RT-PCR):
Reverse transcription reactions for the preparation of
first-strand cDNA from 2 μg of total RNA are performed
using the AffinityScript™ Multi Temperature cDNA syn-
thesis kit, (Stratagene, La Jolla, CA, USA). Random
primers are used as amplification primers.
Real-time PCR:
Transcript levels of PAD2 & PAD4 were determined
using the Mx3000P Real-Time PCR system (Stratagene)
and SYBR® Green I Master Mix (Stratagene) according
to the manufacturer’s instructions. Primers sequences
are shown below:
PADI 2 For: 5′- AAAGGCTTGGGTGGGATGAG-3’.
PADI 2 Rev.: 5′- GGCTCTCGTTGGACAGAATCTT-3’.
PADI 4 For: 5′- CCTGAAGGAGTTTCCCATCAA -3’.
PADI 4 Rev.: 5′- GGTTCCCAAAGGAGTCCAGT -3’.
Actin was used as internal control to normalize PADI2
and PADI4 mRNA expression levels, as previously de-
scribed [28].
Western blot
1 million BALF cells were lysed in RIPA buffer (R0278-
Sigma, Europe) supplemented with protease inhibitor
(HALT protease inhibitor, 1,860,932, Thermo Scientific,
Europe) and 30 μg total protein were mixed with
NuPAGE LDS 4Χ LDS Sample Buffer (Invitrogen Corp.,
USA) and separated by 12% SDS-polyacrylamide gel
electrophoresis. The proteins were then transferred elec-
trophoretically to a nitrocellulose membrane (0.45 μm)
(Bio-Rad, Europe). After blocking non-specific epitopes
with blotting buffer, membranes were incubated overnight
with anti-PADI2 mouse monoclonal antibody (ab-56,928
Abcam-UK) or anti-PADI4 mouse nonoclonal antibody
(ab-57,167, Abcam-UK). Horseradish peroxidase-linked
anti-mouse immunoglobulin G (IgG) was used as second-
ary antibody and immunodetection was performed with
enhanced chemiluminescence (ECL) Luminata Forte
(WBLUF0100-Millipore USA), The mouse anti-actin anti-
body (MAB 1501, Chemicon, Temecula, CA) was used in
order to normalize PADI2 and PADI4 expression. Mem-
branes were visualised with Bio-Rad ChemiDoc XRSplus
and semi-quantative analysis by densitometry was per-
formed using the BioRad-Image Lab software.
Immunocytochemistry
BALF cytospins from four (4) controls, six (6) IPF and
five (5) RA-ILD were mounted on charged glass slides
and immunohistochemical detection of PADI2 and
PADI4 protein expression was assessed using mouse
monoclonal primary antibodies anti-PADI2 and anti-
PADI4 as described above. Briefly, cytospin slides were
incubated with the primary anti-PADI4 and anti PADI2
antibodies, for one hour at room temperature. Negative
controls were obtained by omitting primary antibody.
Antibody binding was detected by means of the UltraVi-
sion Quanto Detection System HRP DAB (Thermo
Scientific), without any pre-treatment and according to
the manufacturer’s instructions. Colour was developed
by 15 min incubation with DAB solution and slides were
weakly counterstained with Mayer’s haematoxylin. Immu-
nostaining evaluation was performed by two separate pa-
thologists (AK & EL), assessing the presence of cytoplasmic
staining on macrophages, neutrophils and eosinophils.
Evaluation of protein citrullination
40 μg total protein samples were separated as described
above and transferred on to PVDF membranes, followed
by citrulline modification using the AMC detection kit
reagents (Cat.# 17-347B, Millipore, USA) as described
by the manufacturer. The membranes were subsequently
analysed as describe above, using the anti-modified cit-
rulline human monoclonal antibody (MABS487, Milli-
pore USA) and secondary HRP-conjugated anti-human
antibody included in the AMC detection kit.
Statistical analysis
Analyses were performed with Graphpad 6.0. Group
comparisons were made by analysis of variance, Student
t test, Wilcoxon rank-sum test, or chi-square testing as
appropriate. A P value less than 0.05 was considered sta-
tistically significant.
PADI2 and 4 mRNA and protein levels results were first
evaluated by D’Agostino-Pearson omnibus normality test.
Values reported are median with min and max. Mann-
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Whitney test was used to examine PADIs expression sta-
tus among IPF, RA-ILD patient groups and controls.
Results
Demographic data and PFTs are summarised in Table 1.
The three groups were age matched, while the IPF and con-
trol group consisted mainly of males, whereas the RA-ILD
group consisted more females (12/27).
PADI4 expression in BAL cells
PADI4 mRNA transcripts were higher in RA-ILD and IPF
compared to controls (p = 0.005 and p = 0.019) (Fig. 1a
and Table 2). In RA-ILD, PADI4 levels tended to be higher
than in IPF (median fold change 2.6). PADI4 levels did not
vary with age, gender or CPI levels in RA-ILD.
In RA-ILD, PADI4 levels were higher in smokers (ex
and current) than non-smokers (mean ± SD: 1.3E-05 ±
2.8E-06 vs 2.8E-05 ± 5.9E-06 p = 0.035, t-test) and showed
a marginal positive correlation with packyears (pearson
r:0.59, p = 0.082). Since the control group, consisted
exclusively of smokers, we performed a second analysis
with ever smokers from each disease group and observed
that PADI4 levels remained significantly higher in RA-ILD
and IPF compared to controls (Kruskal-Wallis test,
p = 0.005) (Table 2).
Subsequently, we evaluated the protein levels of PADI4
in BAL cells (Fig. 2a and b). PADI4 was significantly
higher in RA-ILD compared to controls (Mann-Whitney
test p = 0.0043), and marginally elevated compared to
IPF (p = 0.051). Notably, 50% (4/8) of IPF patients, and
all RA-ILD patients tested had detectable PADI4 protein
levels by western blot in contrast to controls. PADI4 im-
munostaining was mainly observed in neutrophils and
eosinophils, with occasional monocyte/macrophage posi-
tive cells, in RA-ILD and in a subset of IPF patients (Fig. 3a
and b). Controls and a group of IPF exhibited, mainly
monocyte/macrophage cytoplasmic staining and less pro-
nounced neutrophil PADI4 expression (Fig. 3c and d).
PADI2 expression in BAL cells
PADI2 mRNA levels were significantly lower in IPF and
RA-ILD compared to controls (p = 0.023 and p = 0.001
respectively) and in RA-ILD compared with IPF (p =
0.018) (Fig. 1b and Table 2), however PADI2 levels
were similar in all groups in ever smokers. PADI2
protein levels were detectable, by western blot, in 2/
6 RA-ILD and 1/11 IPF patients and not in controls
(Additional file 1: Fig. S1). Immunostaining of BAL cells
revealed similar expression of PADI2 in all groups albeit,
stronger staining was observed in current smokers. (Data
not shown).
Protein Citrullination levels
Given the increased PADI4 expression in RA-ILD and
IPF, we subsequently evaluated protein citrullination
Table 1 Clinicopathological characteristics of all subjects studied
Characteristics Controls IPF RA-ILD p value
Number 10 59 27
Age 56.6 ± 8.6 64.17 ± 10.41 63.3 ± 10 C vs IPF vs RA-ILD ns*
Gender (male/female) 10/0 45/14 15/12 C vs IPF ns**
IPF vs RA-ILD ns
p < 0.05 C vs RA-ILD
Non-smokers vs ever-smokers 10/0 36/23 14/13 C vs IPF vs RA-ILD ns**
Py 49.6 ± 8 30.9 ± 21 43.3 ± 43 p < 0.01 C > IPF***
RA-ILD vs IPF vs C ns
P < 0.01 C > IPF*
FEV1% pred 76.82 ± 17.09 80.9 ± 22 RA-ILD vs IPF*
FVC % pred 73.9 ± 18.08 81.1 ± 24.7 RA-ILD vs IPF ns*
DLco % pred 43.45 ± 13.4 51.9 ± 14.3 P < 0.05 IPF < RA***
CPI (units) 50.69 ± 13.02 42.6 ± 15.5 P < 0.01 IPF > RA*
Macrophages(%) 77.7 ± 13 76.37 ± 11.45 65,1 ± 20.55 C vs RA-ILD vs IPF Ns*
Lymphocytes(%) 18.7 ± 10 9.9 ± 7.9 25.5 ± 20.3 p < 0.001 IPF < RA-ILD*C
vs RA vs IPF ns
Polymorphonuclear(%) 1.3 ± 1.5 10.9 ± 11.5 7.8 ± 4.9 C vs IPF vs RA-ILD ns*
Eosinophils (%) 0 4.6 ± 5 2.5 ± 1.8 C vs IPF vs RA-ILD ns*
Values are expressed as means ± standard deviations
*Ordinary one-way ANOVA; P < 0.05, following bonferroni adjustment, is considered statistically significant
**χ2 test; P < 0.05, following Bonferroni adjustment, is considered statistically significant
***Kruskal-Wallis test, P < 0,05, following Dunn’s adjustment is considered statistically significant
Abbreviations: FEV1: forced expiratory volume in one second, FVC: forced vital capacity, DLCO: diffusing capacity for carbon monoxide, C: controls, py: packet years
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levels. BAL cells from three (3) control, six (6) IPF and
six (6) RA-ILD subjects were analyzed by immunoblot-
ting following chemical modification of citrulline resi-
dues. As shown in Fig. 4a, citrullinated proteins were
present in all groups. Two main bands were detected,
the most prominent had a molecular weight of ~26 kDa
and a less prominent of ~54 kDa. Overall, in IPF,
citrullinated proteins were higher compared to con-
trols (t-test with Welch correction p = 0.03) and RA-
ILD (p = 0.04) (Fig. 4b).
Notably, although the mean levels of citrullinated pep-
tides were similar in RA-ILD and controls (Fig. 3b) a large
variation in protein citrullination was observed in RA-
ILD. Further analysis of the RA-ILD group showed that
high levels of citrullinated proteins were observed only in
ACPA positive subjects (3/5) (pearson r = 0.96, p = 0.009,
n = 5). Furthermore, in RA-ILD citrullinated proteins
levels positively correlated with PADI4 expression (pear-
son r = 0.9, p = 0.03, n = 5). In contrast, no correlation of
citrullinated proteins and PADI4 expression was observed
in IPF or controls.
Discussion
Idiopathic and autoimmune ILD is associated with ageing
and smoking [21, 22, 29]. We hypothesized that the PADIs/
citrullination pathway may be a common pathogenetic fac-
tor in both IPF and RA-ILD. In the current study, we evalu-
ated the citrullination pathway in the BAL cells of RA-ILD
and IPF patients and we identified an upregulation in both
groups. Specifically, PADI4 mRNA and protein expression
was elevated in RA-ILD and IPF. Pronounced PADI4
expression was observed mainly in neutrophils whilst alveo-
lar macrophages also stained positive with lower intensity.
Additionally, protein citrullination was significantly
increased in IPF compared to controls. Importantly, we
observed that in RA-ILD citrullinated proteins levels posi-
tively correlated with PADI4 protein and ACPAs’ levels, in
contrast to IPF and controls.
a b
Fig. 1 (a) PADI4 and (b) PADI2 relative mRNA expression in IPF, RA-ILD and control subjects were analysed by RT-PCR and normalised to actin. * = p <
0.05, ** = p < 0.01, *** = p < 0.001, Mann-Whitney test
Table 2 mRNA expression profiles of PADI2 and PADI4 in IPF, RA-ILD and Control group. Values are expressed as median with min
and max. Mann-Whitney test was performed for each pair
Controls IPF RA-ILD P- value
N 10 58 26
PADI2
(MIN-MAX)
3,67E-03
(7.7E-04 – 9.6E-03)
1.1E-03
(2.6E-05 – 1.7E-02)
3.7E-04
(9.7E-05 – 2.4E-02)
C vs IPF p = 0.02*
C vs RA p = 0.001
IPF vs RA p = 0.02
PADI4
(MIN-MAX)
5.52 E-07
(0–4.7E-05)
6.01E-06
(0–1.4E-04)
1.57E-05
(0–7.0E-05)
C vs IPF p = 0.019*
C vs RA p = 0.0053
IPF vs RA ns
N-smokers 10 36 14
PADI2
(MIN-MAX)
3,67E-03
(7.7E-04 – 9.6E-03)
1.1E-03
(2.5E-05 – 1.6E-02)
3.9E-04
1.3E-04 – 2.4E-02)
C vs IPF vs RA-ILD ns**
PADI4
(MIN-MAX)
5.52 E-07
(0–4.7E-05)
9.4E-06
(0–1.4E-04)
2.1E-05
(2.8E-06– 7 E-05)
C vs IPF p = 0.019*
C vs RA p = 0.0032
IPF vs RA ns
*Mann-Whitney test
**Unpaired t-test with Welch correction
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Our results suggest that BAL cells from IPF and RA-
ILD patients exhibit increased levels of PADI4 enzyme
that was mainly localized in neutrophils. PADI4 is an or-
chestrator of NETosis, an innate immune response
process involving the citroullination of nuclear histones
and the release of neutrophil extracellular traps (NETs)
in response to pathogen recognition patterns. NETosis
may cause local tissue damage and inflammation with
already notable roles in chronic and acute lung diseases
[30, 31]. NETs are also related to the formation of autoanti-
bodies in various autoimmune diseases [32–34] through ex-
posing citrullinated proteins to the immune system [35]
and have already been associated with established RA [36].
Patients with autoimmune associated ILD showed elevated
levels of circulating cell- free NETs, together with a de-
creased DNase activity [37]. A recent report has established
that NET formation increases with age and is linked to in-
creased interstitial collagen deposition and pulmonary fi-
brosis [38]. PADI4 ablation or DNase I administration
protected mice against age related organ fibrosis, including
pulmonary fibrosis [38]. In IPF, increased number of BAL
neutrophils is a predictor of early death [39] and is linked
to the morphologic extent of disease [40]. It could be spec-
ulated therefore that increased PADI4 expression observed
in our study combined to increased neutrophil infiltration
could be involved in the pathogenesis of IPF through the
prolonged exposure to NETs.
PADI2 levels have been previously correlated with smok-
ing [18] and our study showed that control smokers had
equally elevated mRNA levels of PADI2 as IPF and RA-ILD
smokers. Furthermore, RA-ILD smokers showed higher
levels of PADI4 mRNA expression suggesting an inv-
olvement of smoking in PADI4 expression. Smoking, the
strongest common environmental risk factor for the devel-
opment of chronic lung diseases [22], is associated with the
citrullination pathway [4, 12, 13]. Furthermore, recent stud-
ies in COPD and lung cancer, where smoking is a central
pathogenetic factor, showed increased citrullinated proteins
[41, 42] while increased lung tissue citrullination has been
observed in Interstitial Pneumonias [19, 23].
In the current study we observed that, in RA-ILD,
PADI4 protein levels were upregulated in BAL cells and
a
b
Fig. 2 a) A representative immunoblot of PADI4 intracellular levels in 3 controls, 4 IPF and 3 RA-ILD subjects. b) PADI4 protein expression levels
in IPF, RA-ILD and control subjects relative to actin. The bars represent median with range. ** = p < 0.01, Mann-Whitney test
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positively correlated with intracellular citrullination. We
further examined the extent of protein citrullination and
observed similar levels compared to controls. However,
citrullination was present in all ACPAs positive and absent
in ACPAs negative subjects. Importantly, we observed a
positive correlation between protein citrullination, PADI4
protein and ACPAs’ levels. Protein citrullination has been
strongly associated with autoantibody occurrence [1].
Additionally, functional haplotypes of PADI4 enzyme
leading to increased PADI4 mRNA stability are strongly
associated with RA susceptibility [43]. A current hypoth-
esis in RA pathogenesis suggests that the presence of
ACPAs define a distinct clinical RA phenotype [44], in
which the lung is the site of disease initiation. ACPA posi-
tivity is associated with subclinical interstitial lung abnor-
malities [14] and high titers of ACPAs are associated with
ILD irrespectively of smoking status [45]. Our results
provide the first evidence of a link between PADI4 and
citrullination levels in BAL cells and ACPA positivity, and
is consistent with the notion that the lung is a site of
citrullinated autoantigen production. According to our
knowledge this is the first study suggesting that PADI4 is
upregulated in BAL neutrophils in RA-ILD.
IPF and RA-UIP (the most common pattern of RA-ILD)
share a clinical and mechanistic phenotype [27], therefore,
we also examined the extent of protein citrullination in IPF
patients. We observed a strong upregulation of citrullinated
proteins in IPF, suggesting the activation of the citrullina-
tion pathway. However, we did not detect a correlation be-
tween PADI4 expression and total protein citrullination
suggesting that other PADIs may be involved. Intriguingly,
the detected citrullinated protein(s) at 54 kDa, previously
shown to correspond to enolase, vimentin and/or fibrino-
gen proteins [19] may suggest a possible link with auto-
antibodies against vimentin. Recent findings implicate the
presence of anti-vimentin autoantibodies in IPF pathogen-
esis. Increased anti-vimentin antibodies in the serum and in
BALF and the levels were correlated with clinical features
of the disease [46]. These observations and other findings
provide serological and clinical evidence of immune dysreg-
ulation in IPF [41, 45, 47–50], however, evidence of auto-
immunity in IPF needs to be interpreted with caution [51],
as it can be purely a secondary phenomenon. This question
lies beyond the scope of the current study and requires a
pleotropic approach to the definition of pathogenesis in
future work.
Fig. 3 Representative images of BALF cytospins, stained with anti-PADI4 antibody, from IPF (a) and RA-ILD (b) patients, demonstrated strong cytoplas-
mic staining mostly in polymorphonuclear leukocytes (arrows) and mild stain in some macrophages (arrowheads), whereas in some IPF (c) and control
patients (d) staining was observed mostly in macrophages (arrows) and only in occasional granulocytes (arrowheads). Negative control (e).
Magnification X600
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The current report does not lack limitations. Although
a large number of patient samples was analysed retro-
spectively for mRNA levels, relatively small number of
samples was available for protein studies. Any possible
use of PADI4 as a clinically relevant biomarker or as a
therapeutic target requires larger numbers and ideally a
prospective cohort.
Conclusion
The results of the current study suggest that citrullina-
tion is an active process in both IPF and the rheumatoid
lung, strongly implicating the role of neutrophils. Neu-
trophil activation and NET formation should thus be
further studied as they may provide novel insights in the
pathogenesis of both Idiopathic and Autoimmune Inter-
stitial Pulmonary Fibrosis.
Additional file
Additional file 1: Figure S1. A representative immunoblot of PADI2 in
three (3) control, six (6) IPF and six (6) RA-ILD subjects. PADI2 protein
correspond to the 72kDA band observed. (DOCX 11 kb)
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